HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Henipavirus Infections

Subscribe to New Research on Henipavirus Infections

Infections with viruses of the genus HENIPAVIRUS, family PARAMYXOVIRIDAE.

Also Known As:

Henipavirus Infection; Infection, Henipavirus; Infections, Henipavirus

Networked: 15 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Disease Context: Research Results

Virus Diseases: 1820
- RNA Virus Infections: 103
  - Mononegavirales Infections: 1
    - Paramyxoviridae Infections: 1104
      - Henipavirus Infections: 15

Related Diseases

1.	Infection

Experts

1.	Wang, Lin-Fa: 6 articles (01/2013 - 01/2005)
2.	Horvat, Branka: 3 articles (01/2015 - 01/2013)
3.	Mathieu, Cyrille: 3 articles (01/2015 - 01/2013)
4.	Marsh, Glenn A: 3 articles (01/2013 - 01/2011)
5.	Broder, Christopher C: 3 articles (01/2013 - 01/2005)
6.	Virtue, Elena R: 3 articles (01/2013 - 01/2011)
7.	Crameri, Gary: 3 articles (03/2008 - 01/2005)
8.	Wong, Kum Thong: 2 articles (09/2015 - 02/2013)
9.	Ong, Kien Chai: 2 articles (09/2015 - 02/2013)
10.	Raoul, Hervé: 2 articles (01/2015 - 01/2013)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Henipavirus Infections:

1.	VaccinesIBA 02/01/2013 - "Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines." 09/01/2015 - "Many animal models studied to date have largely confirmed the pathology of henipavirus infection, and provided the means to test new therapeutic agents and vaccines. " 09/01/2010 - "The aim of this article is to discuss the pathology of laboratory animal models of henipavirus infection and to assess their suitability as animal models for the development and testing of human therapeutics and vaccines. " 12/01/2008 - "There are currently no therapeutics or vaccines available to treat Henipavirus infection and both are classified as BSL4 pathogens. "
2.	PeptidesIBA 01/01/2005 - "The improved synthesis and solubility characteristics of the second generation HR-2 peptides will facilitate peptide synthesis for pre-clinical trial application in an animal model of Henipavirus infection. "
3.	InterferonsIBA 04/01/2011 - "In contrast to published transfection studies, our study found that the interferon signaling pathways are only partially blocked by henipavirus infection of human cell lines." 04/01/2011 - "We report that henipavirus infection does not result in interferon production, with the virus antagonizing this response. " 04/01/2011 - "Interferon signaling remains functional during henipavirus infection of human cell lines." 01/01/2011 - "This information, in addition to the known lack of clinical signs in bats following henipavirus infection, suggests that bats control henipavirus infection by an as yet unidentified mechanism, not via the interferon response. " 01/01/2011 - "We report that henipavirus infection does not result in the induction of interferon expression, and the viruses also inhibit interferon signaling. "
4.	Interferon Type IIBA 01/01/2013 - "Altogether, these results reveal IFNAR-KO mice as a new small animal model to study HeV and NiV pathogenesis, prophylaxis, and treatment and suggest the critical role of type I interferon signaling in the control of henipavirus infection." 01/01/2013 - "Type I interferon signaling protects mice from lethal henipavirus infection."
5.	Glycoproteins (Glycoprotein)IBA 03/15/2008 - "Soluble ephrin ligands, their receptors and G-specific human monoclonal antibodies differentially blocked henipavirus infections suggesting different receptor affinities, overlapping receptor binding domains of the henipavirus attachment glycoprotein (G) and that the functional domains of the ephrin ligands may be important for henipavirus binding." 02/01/2007 - "Inhibition of henipavirus infection by Nipah virus attachment glycoprotein occurs without cell-surface downregulation of ephrin-B2 or ephrin-B3."
6.	Ephrin-B3 (Ephrin B3)IBA 02/01/2007 - "Inhibition of henipavirus infection by Nipah virus attachment glycoprotein occurs without cell-surface downregulation of ephrin-B2 or ephrin-B3."
7.	Ephrin-B2 (Ephrin B2)IBA 02/01/2007 - "Inhibition of henipavirus infection by Nipah virus attachment glycoprotein occurs without cell-surface downregulation of ephrin-B2 or ephrin-B3."
8.	Ribavirin (Virazole)FDA LinkGeneric 06/01/2011 - "Although ribavirin was empirically used and seemed beneficial during the biggest outbreak caused by one of these viruses, the Nipah virus, its efficacy is disputed in light of its lack of efficacy in several animal models of henipavirus infection. "
9.	PhosphoproteinsIBA 06/01/2007 - "The longer pair of truncated recombinant phosphoproteins, covering amino acid residues 4-550, was more antigenic than the shorter one and of potential utility in the serological differentiation of henipavirus infections." 06/01/2007 - "Expression of truncated phosphoproteins of Nipah virus and Hendra virus in Escherichia coli for the differentiation of henipavirus infections."
10.	NucleotidesIBA 01/01/2013 - "We further demonstrate that the GFP virus retained the ability to cause fatal disease in a well-characterized ferret model of henipavirus infection despite the genome being an extra 1290 nucleotides in length."

Therapies and Procedures

1.	Therapeutics 09/01/2010 - "The aim of this article is to discuss the pathology of laboratory animal models of henipavirus infection and to assess their suitability as animal models for the development and testing of human therapeutics and vaccines. " 12/01/2008 - "There are currently no therapeutics or vaccines available to treat Henipavirus infection and both are classified as BSL4 pathogens. "